Sanofi (SNYNF) Restructuring Costs (2009 - 2026)
Sanofi (SNYNF) posted Restructuring Costs of -$139.3 million for Q1 2026, up 89.48% sequentially from -$1.3 billion in Q4 2025, and down 26.14% YoY from -$188.6 million in Q1 2025.
Sanofi (SNYNF) Restructuring Costs (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Restructuring Costs data on file, last reported at -$139.3 million in Q1 2026.
- Quarterly Restructuring Costs fell 26.14% year-over-year to -$139.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 billion (down 13.17% YoY) and the FY2025 annual result came in at $1.3 billion, down 11.2% from the prior year.
- Restructuring Costs grew to -$139.3 million in Q1 2026 per SNYNF's latest filing, from -$1.3 billion in the prior quarter.
- The five-year high for Restructuring Costs was -$110.4 million in Q1 2025, with the low at -$1.5 billion in Q4 2024.
- Average Restructuring Costs over 5 years is -$519.5 million, with a median of -$367.9 million recorded in 2025.
- Year-over-year, Restructuring Costs slumped 538.96% in 2023 and soared 83.44% in 2025.
- Sanofi's Restructuring Costs stood at -$173.4 million in 2022, then tumbled by 538.96% to -$1.1 billion in 2023, then sank by 34.61% to -$1.5 billion in 2024, then gained by 11.2% to -$1.3 billion in 2025, then jumped by 89.48% to -$139.3 million in 2026.
- Business Quant data shows SNYNF's Restructuring Costs at -$139.3 million in Q1 2026, -$1.3 billion in Q4 2025, and -$703.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -139.32 Mn |
| Dec 31, 2025 | -1.32 Bn |
| Sep 30, 2025 | -703.77 Mn |
| Jun 30, 2025 | -367.89 Mn |
| Mar 31, 2025 | -110.45 Mn |
| Dec 31, 2024 | -1.49 Bn |
| Sep 30, 2024 | -158.14 Mn |
| Jun 30, 2024 | -480.29 Mn |
| Mar 31, 2024 | -667.03 Mn |
| Dec 31, 2023 | -1.11 Bn |
| Sep 30, 2023 | -281.94 Mn |
| Jun 30, 2023 | -334.30 Mn |
| Mar 31, 2023 | -257.60 Mn |
| Dec 31, 2022 | -173.44 Mn |
| Sep 30, 2022 | -377.09 Mn |
| Jun 30, 2022 | -658.37 Mn |
| Mar 31, 2022 | -196.41 Mn |
| Dec 31, 2021 | -372.93 Mn |
| Sep 30, 2021 | -206.38 Mn |
| Jun 30, 2021 | -225.20 Mn |